United TherapeuticsUTHR +3.03%88 PS Ratio is 8.45 as of Jul. 08, 2026, which is 75% above its 10-year median of 4.83. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.86 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, United Therapeutics ranks worse than 84.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, United Therapeutics's share price is $563.70.
United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $66.70. Hence, United Therapeutics's PS Ratio for today is 8.45.
Warning Sign:
United Therapeutics Corp stock PS Ratio (=8.45) is close to 10-year high of 8.82.
The historical rank and industry rank for United Therapeutics's PS Ratio or its related term are showing as below:
UTHR'
s PS Ratio Range Over the Past 10 Years
Min: 2.12 Med: 4.83 Max: 8.82
Current: 8.45
During the past 13 years, United Therapeutics's highest PS Ratio was 8.82. The lowest was 2.12. And the median was 4.83.
UTHR's PS Ratio is ranked worse than 84.03% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs UTHR: 8.45
United Therapeutics Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of United Therapeutics was 7.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 18.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 15.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.80% per year.
During the past 13 years, United Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 260.90% per year. The lowest was -4.70% per year. And the median was 25.80% per year.
Back to Basics: PS Ratio
United Therapeutics (NAS:UTHR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
United Therapeutics PS Ratio Related Terms
United Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for United Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where United Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
United Therapeutics's Share Price of today is $563.70. United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $66.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
United Therapeutics (UTHR) has a PS Ratio of 8.45 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on United Therapeutics and its competitors. This is 75% above median its historical median of 4.83. Over the past decade, United Therapeutics' PS Ratio has ranged from 2.12 to 8.82. According to the industry distribution chart, United Therapeutics ranks #800 out of 952 companies in the Drug Manufacturers industry, placing it in the top 84%.
Is United Therapeutics' PS Ratio too high?
United Therapeutics' current PS Ratio of 8.45 is 75% above median its 10-year median of 4.83. Over the past 10 years, this metric has ranged from a low of 2.12 to a high of 8.82. The Drug Manufacturers industry median PS Ratio is 2.29. United Therapeutics' value of 8.45 is 269% above this industry median. Based on the distribution chart, United Therapeutics ranks #800 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' PS Ratio compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #800 out of 952 companies for PS Ratio. This places United Therapeutics in the lower half of its industry. The industry median PS Ratio is 2.29. United Therapeutics' value of 8.45 is 269% above this benchmark. Historically, United Therapeutics' own PS Ratio has ranged from 2.12 to 8.82 over the past decade. While the company's 10-year median is 4.83 vs. the industry median of 2.29, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current PS Ratio of 8.45 is 269% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current PS Ratio is 8.45, which is 75% above median its own 10-year median of 4.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.86, compared to a current price of $563.70 — trading 45.7% above its estimated fair value. The current PS Ratio is 8.45, which is 75% above median its 10-year median of 4.83 and 269% above the Drug Manufacturers industry median of 2.29. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For United Therapeutics (UTHR), the current PS Ratio is 8.45 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $563.70 is trading 45.7% above its estimated GF Value™ of $386.86.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
PS Ratio: 8.45 (75% above median its 10-year median of 4.83)
GF Value™: $386.86 vs. price of $563.70 (45.7% above fair value)
Industry Position: 269% above the Drug Manufacturers median (#800 of 952)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
